MGI PHARMA, INC. (Nasdaq: MOGN) summarized interim results from a phase 2 combination ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE